Exane Derivatives’s AstraZeneca AZN Stock Holding History

Exane Derivatives’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-13	Closed	-$124K	–	578
2017 Q2	$124K	Buy	+13	New	+$849	0.03%	253
2017 Q1	–	Sell	-225	Closed	-$346K	–	578
2016 Q4	$346K	Hold	225	–	–	0.07%	181
2016 Q3	$115K	Buy	+225	New	+$14.7K	0.02%	235
2015 Q4	–	Sell	-50	Closed	-$28.7K	–	521
2015 Q3	$28.7K	Sell	50 -100	-67%	-$6.58K	﹤0.01%	303
2015 Q2	$51.6K	Buy	150 +100	+200%	+$6.85K	0.01%	286
2015 Q1	$17.6K	Hold	50	–	–	﹤0.01%	361
2014 Q4	$29.6K	Buy	+50	New	+$3.58K	﹤0.01%	355

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Exane Derivatives's AZN Position: Q3 2017 in Review

Exane Derivatives sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 11,577 shares — an estimated $731K sold.

Exane Derivatives first reported a position in AZN in Q4 2014 and held it in 5 quarters. The position peaked at $8.06M in Q3 2016. 454 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

Exane Derivatives reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
Exane Derivatives sold 11,577 AstraZeneca shares in Q3 2017, an estimated $731K.
Exane Derivatives first reported a position in AstraZeneca in Q4 2014 and held it in 5 quarters.
Exane Derivatives's AstraZeneca position peaked at $8.06M in Q3 2016.
454 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on Exane Derivatives's 13F filing for Q3 2017, filed 18 Oct 2017.